Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146

B -- PROCESS BLOOD CULTURE AND PERFORM TESTING, SEROTYPING AND MOLECULAR TYPNG OF ISOLATES TO IDENTIFY THE PATHOGENS OF BLOODSTREAM SOL 2000-Q-00197 DUE 091100 POC Susan Lyle, Purchasing Agent, Phone (770)488-2627, Fax (770)488-2670, Email SLyle@CDC.GOV -- Susan Lyle, Purchasing Agent, Phone (770)488-2627, Fax (770)488-2670, Email SLyle@CDC.GOV WEB: Visit this URL for the latest information about this, http://www2.eps.gov/cgi-bin/WebObjects/EPS?ACode=P&ProjID=2000-Q-00197&LocID=2965. E-MAIL: Susan Lyle, SLyle@CDC.GOV. To determine the roll of emerging pathogens causing bloodstream infections, isolates have been obtained from blood was drawn from hospitalized patients in Vietnam, Brazil and Colombia. The Centers for Disease Control and Prevention intends to procure services of a vendor to perform testing, and provide the results of testing, of these isolates. The following testing is required: (a) analysis on a minimum 2500 Myco F/Lytic bottles and agar slants for bacterial, mycrobacterial and fungal growth, identifying all organisms to the species level; (b) confirm the identities on the following frozen isolates: bacteria (200), mycobacteria (80), and fungi (25); (c) Confirm identities of all frozen isolates; (d) Perform antimicrobial susceptibility testing of all isolates; (e) Perform Serotyping of all non-typhi Salmonella isolates; (f) Perform molecular typing of all M. tuberculosis isolates; and (g) Perform pulsed- field gel electrophoresis on Salmonella isolates. In order to perform the required services, a laboratory must be accredited by the College of American Pathologists, and must be a large-volume diagnostic/research facility with reference laboratory-level expertise in the isolation and identification of fungi and mycobacteria. Personnel must have ten or more years experience conducting comparative blood culture studies with documented publications of these studies in the peer-reviewed medical literature. In addition, the laboratory should have recent (over the past three years) experience conducting bloodstream infection studies in sub-Saharan Africa, Southeast Asia, and South America, and culturing blood from patients in these regions for unexpected and emerging bacteria, mycobacteria, and fungi. The laboratory must have approved Biosafety level III containment facilities (detailed in "Biosafety in Microbiology and Biomedical Laboratories" HHS Publication 93-8395) to safely handle unknown, often dangerous, emerging pathogens responsible for bloodstream infections. A sole source procurement is anticipated with Duke University Medical Center, Clinical Microbiology Laboratory (CML). The basis for this sole source is CML's knowledge and experience in conducting blood culture studies and performing susceptibility testing in HIV-endemic regions in Tanzania, Malawi, Thailand and Vietnam. All interested parties are requested to submit a written request to be provided an RFQ package. Inquiries must reflect the RFQ number. Point of Contact is Sue Lyle at the above address, Mailstop K70, or via e-mail at SIL2@cdc.gov, or by facsimile at 770-488-2670 or 2671. A Request for Quotations will be issued on approximately September 13, 2000. SIC 8221 Posted 08/25/00 (D-SN490142). (0238)

Loren Data Corp. http://www.ld.com (SYN# 0011 20000829\B-0002.SOL)

| B - Special Studies and Analyses - Not R&D Index  |  Issue Index |